ライフサイエンスコーパス: alveolar rhabdomyosarcoma

1 nhibitors holds promise for the treatment of alveolar rhabdomyosarcoma.

2 adiosensitizer for the clinical treatment of alveolar rhabdomyosarcoma.

3 dismal prognosis for invasive or metastatic alveolar rhabdomyosarcoma.

4 IR) is an essential component of therapy for alveolar rhabdomyosarcoma.

5 e use of fusion gene status to risk stratify alveolar rhabdomyosarcoma.

6 binding sites and associated target genes in alveolar rhabdomyosarcoma.

7 n gene is associated with the development of alveolar rhabdomyosarcoma.

8 ional organisation of the fused landscape in alveolar rhabdomyosarcoma.

9 ltured cells from a common pediatric cancer, alveolar rhabdomyosarcoma.

10 cipal for PDGFR-A as a therapeutic target in alveolar rhabdomyosarcoma.

11 ate cancer vaccine for HLA-B7+ patients with alveolar rhabdomyosarcoma.

12 al translocation, a unique genetic marker of alveolar rhabdomyosarcoma.

13 1 is frequently found in Ewing's sarcoma and alveolar rhabdomyosarcoma.

14 3) chromosomal translocation associated with alveolar rhabdomyosarcoma.

15 al translocation seen in the pediatric tumor alveolar rhabdomyosarcoma.

16 ling, is a downstream target of PAX3-FKHR in alveolar rhabdomyosarcoma.

17 AX3 and FKHR is characteristic of most human alveolar rhabdomyosarcomas.

18 gion was unmethylated in the majority of the alveolar rhabdomyosarcomas (13 of 15, 87%) examined in t

19 scle tumors that resembled the human form of alveolar rhabdomyosarcoma, a cancer associated with poor

20 translocation occurs at a high frequency in alveolar rhabdomyosarcoma, a common pediatric tumor of m

21 In the pediatric solid tumor alveolar rhabdomyosarcoma, a consistent t(2;13)(q35;q14)

22 13) translocation present in 80% of cases of alveolar rhabdomyosarcoma, a highly aggressive pediatric

23 ) and t(1;13)(p36;q14) are characteristic of alveolar rhabdomyosarcoma, a pediatric soft tissue cance

24 st that PKCiota is functionally important in alveolar rhabdomyosarcoma anchorage-independent growth a

25 osarcoma cell lines, independent of lineage (alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma

26 s model offers new insight into the roots of alveolar rhabdomyosarcoma and illustrates the utility of

27 The Pax3-FKHR fusion protein is present in alveolar rhabdomyosarcoma and results from the t(2;13) (

28 In alveolar rhabdomyosarcoma and synovial sarcoma, these va

29 Alveolar rhabdomyosarcomas are associated with unique ch

30 the successful purification of RNA from the alveolar rhabdomyosarcoma (ARMS) cancer cell line, with

31 gene expression profile of a group of seven alveolar rhabdomyosarcoma (ARMS) cell lines characterize

32 Alveolar rhabdomyosarcoma (ARMS) cells often harbor one

33 tologic variant of rhabdomyosarcoma known as alveolar rhabdomyosarcoma (ARMS) have a 5-year survival

34 the PAX3-FKHR and PAX7-FKHR gene fusions in alveolar rhabdomyosarcoma (ARMS) indicated that the corr

35 Alveolar rhabdomyosarcoma (ARMS) is a devastating pediat

36 Alveolar rhabdomyosarcoma (ARMS) is a muscle-derived chi

37 Alveolar rhabdomyosarcoma (aRMS) is an aggressive childh

38 Alveolar rhabdomyosarcoma (aRMS) is an aggressive myogen

39 Alveolar rhabdomyosarcoma (ARMS) is an aggressive myogen

40 Alveolar rhabdomyosarcoma (ARMS) is an aggressive pediat

41 Alveolar rhabdomyosarcoma (ARMS) is an aggressive pediat

42 Alveolar rhabdomyosarcoma (aRMS) is an aggressive sarcom

43 Alveolar rhabdomyosarcoma (ARMS) is consistently associa

44 The highly aggressive muscle cancer alveolar rhabdomyosarcoma (ARMS) is one of the most comm

45 The t(2;13) and t(1;13) translocations of alveolar rhabdomyosarcoma (ARMS) result in chimeric PAX3

46 a mouse model of the childhood muscle cancer alveolar rhabdomyosarcoma (ARMS) that is driven by the c

47 ted by the 2;13 chromosomal translocation in alveolar rhabdomyosarcoma (ARMS), a cancer associated wi

48 muscle development and is a key component in alveolar rhabdomyosarcoma (ARMS), a childhood solid musc

49 To put the concept into use, we selected alveolar rhabdomyosarcoma (ARMS), a myogenic pediatric c

50 1 fusion transcription factor, which induces alveolar rhabdomyosarcoma (aRMS), an aggressive cancer o

51 Alveolar rhabdomyosarcoma (aRMS), an aggressive skeletal

52 slocation occurs in most cases of the cancer alveolar rhabdomyosarcoma (ARMS), and juxtaposes the gen

53 s remain dismal for patients with metastatic alveolar rhabdomyosarcoma (aRMS), where the chimeric tra

54 Among RMS subtypes, alveolar rhabdomyosarcoma (ARMS), which is characterized

55 Alveolar rhabdomyosarcomas (ARMS) are aggressive soft-ti

56 Alveolar rhabdomyosarcomas (ARMS) are highly malignant s

57 Alveolar rhabdomyosarcomas (ARMS) escape terminal differ

58 In contrast, alveolar rhabdomyosarcomas (ARMS) have fewer genetic les

59 In alveolar rhabdomyosarcomas (ARMSs), a specific chromosom

60 R fusion protein is present in a majority of alveolar rhabdomyosarcomas associated with increased agg

61 ormal conditions, while in a patient-derived alveolar rhabdomyosarcoma cell line, harbouring the diag

62 BP5, HSIX1, and Slug) were also expressed in alveolar rhabdomyosarcoma cell lines.

63 acy of radiation therapy in the treatment of alveolar rhabdomyosarcoma cells and xenografts.

64 In the pediatric cancer alveolar rhabdomyosarcoma, characteristic t(2;13)(q35;q1

65 (2;13)(q35;q14) chromosomal translocation in alveolar rhabdomyosarcoma, consists of the two Pax3 DNA

66 Embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma constitute the two major subty

67 The chromosomal translocation that leads to alveolar rhabdomyosarcoma development generates a novel

68 oma includes two histolopathologic subtypes: alveolar rhabdomyosarcoma, driven by the fusion protein

69 In contrast, we propose that alveolar rhabdomyosarcomas either originate from a late

70 On average, alveolar rhabdomyosarcomas expressed at least threefold

71 ater understanding of the means by which the alveolar rhabdomyosarcoma gene fusions (PAX-FKHR) lead t

72 The 2;13 chromosomal translocation in alveolar rhabdomyosarcoma generates the chimeric protein

73 spontaneous nor a transgenic mouse model of alveolar rhabdomyosarcoma has yet been reported.

74 Furthermore, these murine alveolar rhabdomyosarcomas have an immunohistochemical p

75 3), Craniofacial-deafness-hand syndrome and alveolar rhabdomyosarcoma in humans and the Splotch phen

76 mary mutations and metastatic progression of alveolar rhabdomyosarcomas in humans, we found by immuno

77 Alveolar rhabdomyosarcoma is a pediatric disease specifi

78 Alveolar rhabdomyosarcoma is an aggressive childhood mus

79 Alveolar rhabdomyosarcoma is an aggressive pediatric can

80 Alveolar rhabdomyosarcoma is an aggressive pediatric can

81 Alveolar rhabdomyosarcoma is an aggressive skeletal musc

82 Pediatric alveolar rhabdomyosarcoma is characterized by a chromoso

83 Alveolar rhabdomyosarcoma is characterized by a t(2;13)(

84 observed in 22 of 26 rhabdomyosarcomas, all alveolar rhabdomyosarcomas (nine of nine) showed high le

85 In these mice, alveolar rhabdomyosarcomas occur but at low frequency, a

86 are generally cured, although patients with alveolar rhabdomyosarcoma or undifferentiated sarcoma, p

87 s sarcoma patient samples, and in one of one alveolar rhabdomyosarcoma patient sample.

88 ed to overexpress PAX3-FKHR and PAX7-FKHR in alveolar rhabdomyosarcoma, presumably due to differences

89 The t(2;13) translocation of alveolar rhabdomyosarcoma results in tumor-specific expr

90 immunohistochemical profile similar to human alveolar rhabdomyosarcoma, suggesting that this conditio

91 view, we specifically focus on embryonal and alveolar rhabdomyosarcoma, synovial sarcoma, and adult s

92 Six of seven alveolar rhabdomyosarcomas that strongly stained for myo

93 suggesting that PAX3-FKHR exerts its role in alveolar rhabdomyosarcomas through dysregulation of PAX3

94 The t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma tumors (ARMS) creates an oncog

95 c translocations (two synovial sarcomas, two alveolar rhabdomyosarcomas, two desmoplastic round cell

96 We report the first mouse model of alveolar rhabdomyosarcoma using a conditional Pax3:Fkhr

97 e translocation-associated gene Pax3:Fkhr in alveolar rhabdomyosarcomas, we generated a Cre-mediated